Inovio announces survival results for ino-5401 + ino-9012 in combination with libtayo® (cemiplimab) in patients with newly diagnosed gbm at asco annual meeting 2022

Inovio's dna medicines immunotherapy in combination with libtayo® elicits vaccine-associated immune responses when administered with rt/tmz to newly diagnosed gbm patients ino-5401 + ino-9012 + libtayo ®  elicits cancer antigen-specific t cells 55% of mgmt methylated subjects remain alive at a median of 32.5 months dr. david reardon, principal investigator, to present on june 6, 2022 at asco plymouth meeting, pa. , may 27, 2022 /prnewswire/ -- inovio (nasdaq: ino) announced results from the company's novel phase 1/2 trial of ino-5401 and ino-9012 in combination with pd-1 inhibitor libtayo® (cemiplimab) in the treatment of newly diagnosed glioblastoma (gbm), including encouraging median overall survival (os) data from fifty-two subjects.
INO Ratings Summary
INO Quant Ranking